LUMINEX CORPORATION (NASDAQ:LMNX) Files An 8-K Regulation FD DisclosureItem 7.01 of the Current Report on Form 8-K filed on October23, 2017 (the “Original Form 8-K”) solely to correct a chart label on slide 27 of the investor presentation furnished as Exhibit 99.1 thereto (the “Exhibit”). As previously furnished, slide 27 of the Exhibit reflected incorrect labeling in the chart captioned “MDx Revenue, Automated and Non-Automated,” which has been corrected on Exhibit 99.1 to this Amendment No.1. No other changes have been made to the Original Form 8-K.
Item 7.01. Regulation FD Disclosure.
The Exhibit 99.1 attached hereto includes a replacement of slide 27 of the Exhibit furnished on the Original Form 8-K. The foregoing information is furnished to Item 7.01 Regulation FD Disclosure and shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 7.01. Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit No. |
Description |
LUMINEX CORP ExhibitEX-99.1 2 investordeckf1event2017f.htm EXHIBIT 99.1 investordeckf1event2017f October 21,…To view the full exhibit click here
About LUMINEX CORPORATION (NASDAQ:LMNX)
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company’s assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease.